文献速递白血病造血干细胞移植与细胞治疗

HLH样毒性预测B-ALL儿童及年轻成人使用tisagenlecleucel后的不良生存

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
PubMed 文献 · Blood Adv · 2023-01-01

基于185例接受tisagenlecleucel的B-ALL儿童及年轻成人多机构回顾性队列,26例(14.1%)符合HLH样毒性标准。HLH样毒性组1年总生存和无复发生存分别为25.7%和4.7%,无HLH样毒性组分别为80.1%和57.6%。多变量分析中HLH样毒性与死亡风险升高相关(HR 4.61,95%CI 2.41-8.83)。

要点

  • 185例中26例(14.1%)发生HLH样毒性。
  • HLH样毒性组1年总生存25.7%,无HLH样毒性组80.1%。
  • 控制疾病负荷、年龄和性别后,HLH样毒性与死亡风险升高相关(HR 4.61)。

核心结论

  • 接受tisagenlecleucel后发生HLH样毒性的B-ALL儿童及年轻成人复发和非复发死亡率高,亟需进一步研究预防和最佳管理。

研究设计与样本

  • 多机构数据库回顾性队列研究,纳入185例接受tisagenlecleucel的B-ALL儿童及年轻成人,分为发生HLH样毒性组、无HLH样毒性的高级别CRS组和无至低级别CRS组。

主要发现

  • 185例中26例(14.1%)符合HLH样毒性标准。
  • HLH样毒性组1年总生存25.7%、无复发生存4.7%,无HLH样毒性组分别为80.1%和57.6%。
  • 多变量死亡分析中,符合HLH样毒性标准的风险比HR 4.61(95%CI 2.41-8.83),控制疾病负荷、年龄和性别。
  • 发生HLH样毒性者较无HLH样毒性的高级别或无至低级别CRS者,tisagenlecleucel前疾病负荷、铁蛋白和C反应蛋白水平更高,血小板和中性粒细胞绝对计数更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor-associated hemophagocytic lymphohistiocytosis (HLH)-like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger outcomes analyses of children and young adults (CAYAs) with B-ALL who develop these toxicities after the administration of commercially available tisagenlecleucel are not described. Using a multi-institutional database of 185 CAYAs with B-ALL, we conducted a retrospective cohort study including groups that developed HLH-LTs, high-grade (HG) CRS without HLH-LTs, or no to low-grade (NLG) CRS without HLH-LTs. Primary objectives included characterizing the incidence, outcomes, and preinfusion factors associated with HLH-LTs. Among 185 CAYAs infused with tisagenlecleucel, 26 (14.1%) met the criteria for HLH-LTs. One-year overall survival and relapse-free survival were 25.7% and 4.7%, respectively, in those with HLH-LTs compared with 80.1% and 57.6%, respectively, in those without. In multivariable analysis for death, meeting criteria for HLH-LTs carried a hazard ratio of 4.61 (95% confidence interval, 2.41-8.83), controlling for disease burden, age, and sex. Patients who developed HLH-LTs had higher pretisagenlecleucel disease burden, ferritin, and C-reactive protein levels and lower platelet and absolute neutrophil counts than patients with HG- or NLG-CRS without HLH-LTs. Overall, CAYAs with B-ALL who developed HLH-LTs after tisagenlecleucel experienced high rates of relapse and nonrelapse mortality, indicating the urgent need for further investigations into prevention and optimal management of patients who develop HLH-LTs after tisagenlecleucel.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. McNerney KO, Si Lim SJ, Ishikawa K, et al. HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Adv. 2023. PMID: 36857419. doi:10.1182/bloodadvances.2022008893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。